Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib versus everolimus in previously VEGFR TKI-treated metastatic renal cell carcinoma
NL-OMON40334Phase 3Active, not recruiting
- Sponsor
- Exelixis, Inc.
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cabozantinib and everolimus in renal cell carcinoma (RCC), sponsored by Exelixis, Inc. Started Apr 2014; status: active, not recruiting.
02
Drugs
cabozantinibeverolimus
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON40334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40334.